Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 3, 2011, Pages 484-500

  Loppnow, Harald ^a   Buerke, Michael ^a   Werdan, Karl ^a   Rose John, Stefan ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Atherosclerosis; Cytokine; ECM accumulation; Immunovascular memory; Inflammasome; Inflammation; Innate pathways; Interleukin 1; Interleukin 6; SMC monocyte interaction; Vascular smooth muscle cells

Indexed keywords

EID: 79953331770     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01245.x     Document Type: Article

References (136)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340: 115-26.
2. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6: 508-19.
3. Zhang Y, Cliff WJ, Schoefl GI, et al Plasma protein insudation as an index of early coronary atherogenesis. Am J Pathol. 1993; 143: 496-506.
4. Auffray C, Fogg D, Garfa M, et al Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007; 317: 666-70.
5. Audoy-Remus J, Richard JF, Soulet D, et al Rod-Shaped monocytes patrol the brain vasculature and give rise to perivascular macrophages under the influence of proinflammatory cytokines and angiopoietin-2. J Neurosci. 2008; 28: 10187-99.
6. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 2010; 7: 77-86.
7. Tacke F, Alvarez D, Kaplan TJ, et al Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007; 117: 185-94.
8. Kiechl S, Egger G, Mayr M, et al Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation. 2001; 103: 1064-70.
9. Wiedermann CJ, Kiechl S, Dunzendorfer S, et al Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol. 1999; 34: 1975-81.
10. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010; doi: .
11. Duewell P, Kono H, Rayner KJ, et al NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010; 464: 1357-61.
12. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol. 2006; 2: 99-106.
13. Swirski FK, Libby P, Aikawa E, et al Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007; 117: 195-205.
14. Ingersoll MA, Spanbroek R, Lottaz C, et al Comparison of gene expression profiles between human and mouse monocyte subsets. Blood. 2010; 115: e10-9.
15. Wu H, Gower RM, Wang H, et al Functional role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation. 2009; 119: 2708-17.
16. Mosig S, Rennert K, Krause S, et al Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14+ CD16+ monocytes in detoxification of oxidized LDL. FASEB J. 2009; 23: 866-74.
17. Llodra J, Angeli V, Liu J, et al Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA. 2004; 101: 11779-84.
18. Sun J, Sukhova GK, Wolters PJ, et al Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med. 2007; 13: 719-24.
19. Loppnow H. Cytokines: classification, receptors, mechanisms of action. Internist. 2001; 42: 13-27.
20. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006; 86: 515-81.
21. Fritz JH, Ferrero RL, Philpott DJ, et al NOD-like proteins in immunity, inflammation and disease. Nat Immunol. 2006; 7: 1250-7.
22. Mantovani A, Garlanda C, Doni A, et al Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008; 28: 1-13.
23. Suzuki S, Takeishi Y, Niizeki T, et al Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008; 155: 75-81.
24. Franchi L, Park JH, Shaw MH, et al Intracellular NOD-like receptors in innate immunity, infection and disease. Cell Microbiol. 2008; 10: 1-8.
25. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production Nat Rev Immunol. 2010; 10: 210-5.
26. Alnemri ES. Sensing cytoplasmic danger signals by the inflammasome. J Clin Immunol. 2010; 30: 512-9.
27. Gay NJ, Keith FJ. Drosophila toll and IL-1 receptor. Nature. 1991; 351: 355-6.
28. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature. 1997; 388: 394-7.
29. Roach JC, Glusman G, Rowen L, et al The evolution of vertebrate toll-like receptors. Proc Natl Acad Sci USA. 2005; 102: 9577-82.
30. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009; 22: 240-73.
31. Xu XH, Shah PK, Faure E, et al toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001; 104: 3103-8.
32. Lin FY, Chen YH, Tasi JS, et al Endotoxin induces toll-like receptor 4 expression in vascular smooth muscle cells via NADPH oxidase activation and mitogen-activated protein kinase signaling pathways. Arterioscler Thromb Vasc Biol. 2006; 26: 2630-7.
33. Shinohara M, Hirata K, Yamashita T, et al Local overexpression of toll-like receptors at the vessel wall induces atherosclerotic lesion formation: synergism of TLR-2 and TLR-4. Arterioscler Thromb Vasc Biol. 2007; 27: 2384-91.
34. Michelsen KS, Wong MH, Shah PK, et al Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004; 101: 10679-84.
35. Björkbacka H, Kunjathoor VV, Moore KJ, et al Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004; 10: 416-21.
36. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by toll-like receptor 2. J Clin Invest. 2005; 115: 3149-56.
37. Loppnow H, Werdan K, Buerke M. Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms. Innate Immunity. 2008; 14: 63-87.
38. Loppnow H, Brade H, Dürrbaum I, et al IL-1 induction capacity of defined lipopolysaccharide partial structures. J Immunol. 1989; 142: 3229-38.
39. Auron PE, Webb AC, Rosenwasser LJ, et al Nucleotide sequence of human monocyte interleukin-1 precursor cDNA. Proc Natl Acad Sci USA. 1984; 81: 7907-11.
40. Lomedico PT, Gubler U, Hellmann CP, et al Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature. 1984; 312: 458-62.
41. Singer II, Scott S, Hall GL, et al Interleukin-1ß is localized in the cytoplasmatic ground substance but is largely absent from the golgi apparatus and plasma membranes of stimulated human monocytes. J Exp Med. 1988; 167: 389-407.
42. Kurt-Jones EA, Beller DI, Mizel SB, et al Identification of a membrane-associated interleukin-1 in macrophages. Proc Natl Acad Sci USA. 1985; 82: 1204-8.
43. Loppnow H, Libby P. Functional significance of human vascular smooth muscle cell-derived interleukin-1 in paracrine and autocrine regulation pathways. Exp Cell Res. 1992; 198: 283-90.
44. Westphal E, Chen L, Pilowski C, et al Endotoxin-activated cultured neonatal rat cardiomyocytes express functional surface-associated interleukin-1α. J Endotoxin Res. 2007; 13: 25-34.
45. Black RA, Kronheim SR, Cantrell M, et al Generation of biologically active interleukin-1β by proteolytic cleavage of the inactive precursor. J Biol Chem. 1988; 263: 9437-42.
46. Schönbeck U, Herzberg M, Petersen A, et al Human vascular smooth muscle cells express interleukin-1β-converting enzyme (ICE), but inhibit processing of the interleukin-1β precursor by ICE. J Exp Med. 1997; 185: 1287-94.
47. Westphal E, Herzberg M, Neumann I, et al Neutrophils process IL-1ß and IL-18 precursors in a caspase-1-like fashion - processing is inhibited by human vascular smooth muscle cells. Eur Cytokine Netw. 2006; 17: 19-28.
48. Moyer CF, Sajuthi D, Tulli H, et al Synthesis of IL-1α and IL-1ß by arterial cells in atherosclerosis. Am J Pathol. 1991; 138: 951-60.
49. Loppnow H, Libby P. Proliferating or interleukin-1-activated human vascular smooth muscle cells secrete copious interleukin-6. J Clin Invest. 1990; 85: 731-8.
50. Li J, Perrella MA, Tsai JC, et al Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J Biol Chem. 1995; 270: 308-12.
51. Yue TL, Wang XK, Olson B, et al Interleukin-1 beta (IL-1 beta) induces transforming growth factor-beta, (TGF-beta 1) production by rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1994; 204: 1186-92.
52. Yoshizumi M, Kurihara H, Morita T, et al Interleukin-1 increases the production of endothelin by cultured endothelial cells. Biochem Biophys Res Commun. 1990; 166: 324-9.
53. Beasley D, Cohen RA, Levinsky NG. Interleukin-1 inhibits contraction of vascular smooth muscle. J Clin Invest. 1989; 83: 331-5.
54. Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res. 2008; 79: 14-23.
55. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995; 15: 551-61.
56. Sukhova GK, Shi GP, Simon DI, et al Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998; 102: 576-83.
57. Schlumberger W, Thie M, Rauterberg J, et al Collagen synthesis in cultured aortic smooth muscle cells: modulation by collagen lattice culture, TGF-ß1, and EGF. Arterioscler Thromb. 1991; 11: 1660-6.
58. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb. 2003; 10: 267-74.
59. Gustafsson M, Boren J. Mechanism of lipoprotein retention by the extracellular matrix. Curr Opin Lipidol. 2004; 15: 505-14.
60. Schönherr E, Hausser HJ. Extracellular matrix and cytokines: a functional unit. Dev Immunol. 2000; 7: 89-101.
61. Sun M, Fink PJ. A new class of reverse signaling costimulators belongs to the TNF family. J Immunol. 2007; 179: 4307-12.
62. Ohta H, Wada H, Niwa T, et al Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2005; 180: 11-7.
63. Chandrasekharan UM, Mavrakis L, Bonfield TL, et al Decreased atherosclerosis in mice deficient in tumor necrosis factor-alpha receptor-II (p75). Arterioscler Thromb Vasc Biol. 2007; 27: e16-7.
64. Kirii H, Niwa T, Yamada Y, et al Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003; 23: 656-60.
65. Kamari Y, Werman-Venkert R, Shaish A, et al Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis. 2007; 195: 31-8.
66. Chi H, Messas E, Levine RA, et al Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model - pharmacotherapeutic implications. Circulation. 2004; 110: 1678-85.
67. Isoda K, Shiigai M, Ishigami N, et al Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation. 2003; 108: 516-8.
68. Chamberlain J, Evans D, King A, et al Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am J Pathol. 2006; 168: 1396-403.
69. Devlin CM, Kuriakose G, Hirsch E, et al Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci USA. 2002; 99: 6280-5.
70. Elhage R, Maret A, Pieraggi M-T, et al Differential effects of IL-1 receptor antagonist and TNF binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation. 1998; 97: 242-4.
71. Merhi-Soussi F, Kwak BR, Magne D, et al Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res. 2005; 66: 583-93.
72. Rupprecht HJ, Blankenberg S, Bickel C, et al Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation. 2001; 104: 25-31.
73. Boring L, Gosling J, Cleary M, et al Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 394: 894-7.
74. Gu L, Okada Y, Clinton SK, et al Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998; 2: 275-81.
75. Matsumiya T, Imaizumi T, Fujimoto K, et al Soluble interleukin-6 receptor alpha inhibits the cytokine-Induced fractalkine/ CX3CL1 expression in human vascular endothelial cells in culture. Exp Cell Res. 2001; 269: 35-41.
76. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003; 111: 333-40.
77. Kopf M, Baumann H, Freer G, et al Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994; 368: 339-42.
78. Geiger T, Andus T, Klapproth J, et al Induction of rat acute phase proteins by IL-6 in vivo. Eur J Immunol. 1988; 18: 717-21.
79. 2/BSF-2 shares identity with monocyte derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA. 1987; 84: 7251-5.
80. von Patay B, Loppnow H, Feindt J, et al Catecholamines and lipopolysaccharide synergistically induce the release of interleukin-6 from thymic epithelial cells. J Neuroimmunol. 1997; 86: 182-9.
81. Loppnow H, Libby P. Adult human vascular endothelial cells express the IL-6 gene differentially in response to LPS or IL-1. Cell Immunol. 1989; 122: 493-503.
82. Viedt C, Vogel J, Athanasiou T, et al Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. Arterioscler Thromb Vasc Biol. 2002; 22: 914-20.
83. Watanabe S, Mu W, Kahn A, et al Role of JAK/STAT pathway in IL-6-induced activation of vascular smooth muscle cells. Am J Nephrol. 2004; 24: 387-92.
84. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res. 2003; 58: 186-95.
85. Klouche M, Bhakdi S, Hemmes M, et al Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol. 1999; 163: 4583-9.
86. Ohkawa F, Ikeda U, Kawasaki K, et al Inhibitory effect of interleukin-6 on vascular smooth muscle contraction. Am J Physiol. 1994; 266: H898-902.
87. Lahiri T, Laporte JD, Moore PE, et al Interleukin-6 family cytokines: signaling and effects in human airway smooth muscle cells. Am J Physiol. 2001; 280: L1225-32.
88. Wang Z, Newman WH. Smooth muscle cell migration stimulated by interleukin-6 is associated with cytoskeletal reorganization. J Surg Res. 2003; 111: 261-6.
89. Zhu Y, Hojo Y, Ikeda U, et al Interaction between monocytes and vascular smooth muscle cells enhances matrix metalloproteinase-1 production. J Cardiovasc Pharmacol. 2000; 36: 152-61.
90. Kinlay S, Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol. 2006; 98: 2P-8P.
91. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000; 101: 1372-8.
92. Taga T, Kishimoto T. gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997; 15: 797-819.
93. Müllberg J, Schooltink H, Stoyan T, et al The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993; 23: 473-80.
94. Lust JA, Donovan KA, Kline MP, et al Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine. 1992; 4: 96-100.
95. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994; 300: 281-90.
96. Rose-John S, Scheller J, Elson G, et al Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006; 80: 227-36.
97. Peters M, Jacobs S, Ehlers M, et al The function of the soluble interleukin-6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med. 1996; 183: 1399-406.
98. Althoff K, Mullberg J, Aasland D, et al Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. Biochem J. 2001; 353: 663-72.
99. Diamant M, Rieneck K, Mechti N, et al Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130. FEBS Lett. 1997; 412: 379-84.
100. Jostock T, Müllberg J, Özbek S, et al Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001; 268: 160-7.
101. Cressman DE, Greenbaum LE, DeAngelis RA, et al Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996; 274: 1379-83.
102. Wallenius V, Wallenius K, Ahren B, et al Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002; 8: 75-9.
103. Grivennikov S, Karin E, Terzic J, et al IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009; 15: 103-13.
104. Rose-John S, Mitsuyama K, Matsumoto S, et al Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr Pharm Des. 2009; 15: 2095-103.
105. Chalaris A, Rabe B, Paliga K, et al Apoptosis is a natural stimulus of IL-6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood. 2007; 110: 1748-55.
106. Rabe B, Chalaris A, May U, et al Transgenic blockade of interleukin-6 transsignaling abrogates inflammation. Blood. 2008; 111: 1021-8.
107. Atreya R, Mudter J, Finotto S, et al Blockade of interleukin-6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000; 6: 583-8.
108. Mitsuyama K, Matsumoto S, Rose-John S, et al STAT3 activation via interleukin-6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut. 2006; 55: 1263-9.
109. Hurst SM, Wilkinson TS, McLoughlin RM, et al IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001; 14: 705-14.
110. Nowell MA, Williams AS, Carty SA, et al Therapeutic targeting of IL-6 trans-signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol. 2009; 182: 613-22.
111. Becker C, Fantini MC, Schramm C, et al TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004; 21: 491-501.
112. Matsumoto S, Hara T, Mitsuyama K, et al Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol. 2010; 184: 1543-51.
113. Rose-John S, Waetzig GH, Scheller J, et al The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets. 2007; 11: 613-24.
114. Melton L, Coombs A. Actemra poised to launch IL-6 inhibitors. Nat Biotechnol. 2008; 26: 957-9.
115. Coles B, Fielding CA, Rose-John S, et al Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am J Pathol. 2007; 171: 315-25.
116. Huber SA, Sakkinen P, Conze D, et al Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999; 19: 2364-7.
117. Takeda N, Manabe I, Shindo T, et al Synthetic retinoid Am80 reduces scavenger receptor expression and atherosclerosis in mice by inhibiting IL-6. Arterioscler Thromb Vasc Biol. 2006; 26: 1177-83.
118. Schieffer B, Selle T, Hilfiker A, et al Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 2004; 110: 3493-500.
119. Elhage R, Clamens S, Besnard S, et al Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis. 2001; 156: 315-20.
120. Luchtefeld M, Schunkert H, Stoll M, et al Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man. J Exp Med. 2007; 204: 1935-44.
121. Paul A, Ko KW, Li L, et al C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004; 109: 647-55.
122. Libby P, Ordovas JM, Birinyi LK, et al Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest. 1986; 78: 1432-8.
123. Lukacs NW, Strieter RM, Elner V, et al Production of chemokines, interleukin-8 and monocyte chemoattractant protein-1, during monocyte: endothelial cell interactions. Blood. 1995; 86: 2767-73.
124. Funayama H, Ikeda U, Takahashi M, et al Human monocyte-endothelial cell interaction induces platelet-derived growth factor expression. Cardiovasc Res. 1998; 37: 216-24.
125. Marczin N, Antonov A, Papapetropoulos A, et al Monocyte-induced downregulation of nitric oxide synthase in cultured aortic endothelial cells. Arterioscler Thromb Vasc Biol. 1996; 16: 1095-103.
126. Hojo Y, Ikeda U, Takahashi M, et al Matrix metalloproteinase-1 expression by interaction between monocytes and vascular endothelial cells. J Mol Cell Cardiol. 2000; 32: 1459-68.
127. Kinard F, Jaworski K, Sergent-Engelen T, et al Smooth muscle cells influence monocyte response to LDL as well as their adhesion and transmigration in a coculture model of the arterial wall. J Vasc Res. 2001; 38: 479-91.
128. Hojo Y, Ikeda U, Maeda Y, et al Interaction between human monocytes and vascular smooth muscle cells induces vascular endothelial growth factor expression. Atherosclerosis. 2000; 150: 63-70.
129. Okada M, Hojo Y, Ikeda U, et al Interaction between monocytes and vascular smooth muscle cells induces expression of hepatocyte growth factor. J Hypertens. 2000; 18: 1825-31.
130. Proudfoot D, Fitzsimmons C, Torzewski J, et al Inhibition of human arterial smooth muscle cell growth by human monocyte/macrophages: a co-culture study. Atherosclerosis. 1999; 145: 157-65.
131. Ikeda U, Maeda Y, Funayama H, et al Monocyte-vascular smooth muscle cell interaction enhances nitric oxide production. Cardiovasc Res. 1998; 37: 820-5.
132. Kosuge H, Suzuki J, Haraguchi G, et al Critical role of inducible costimulator signaling in the development of arteriosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26: 2660-5.
133. Chen L, Frister A, Wang S, et al Interaction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances interleukin-6 and MCP-1 production. Am J Physiol. 2009; 296: H987-96.
134. Loppnow H, Zhang L, Buerke M, et al Statins potently reduce the cytokine-mediated IL-6 release in SMC / MNC cocultures. J Cell Mol Med. 2010; doi: .
135. Rock KL, Latz E, Ontiveros F, et al The sterile inflammatory response. Annu Rev Immunol. 2010; 28: 321-42.
136. Tracey KJ. Reflex control of immunity. Nat Rev Immunol. 2009; 9: 418-28.